I have continued to top up at these depressed levels
We have agreements in place with Genentech and Merck which the company refuses to comment on (confidentiality)
There are completed phase 2 trials with ongoing discussions with potential partners for multiple cancer indications
We have commercialised products in the market which up until now have performed abysfully. In regards to this the company (as stated in previous announcement to shareholders) is working hard behind the scenes in order to improve revenues
I remain confident for the future of Starpharma and believe we will be in a far better position before end of calendar year 2024
SPL Price at posting:
9.6¢ Sentiment: Buy Disclosure: Held
